On September 28, 2017, Shenzhen China Resources Gosun Pharmaceutical Co., ltd and a listed Swiss company, Basilea Pharmaceutical International Ltd (SIX: BSLN), successfully executed an exclusive license agreement in relation to Basilea's patented product, the 5th generation cephalosporins antibiotic (ceftobiprole medocaril). Under this agreement, Gosun is entitled to exclusively develop, manufacture and commercialize the ceftobiprole medocaril in mainland China, Hongkong and Macao. China is now facing a situation that the antibiotic resistance is rapidly increasing but the R&D of new antibiotic is severely inadequate. While the introduction of the 5th generation cephalosporins antibiotic into China definitely will in a certain way relieve the pressure and benefit the patients, especially those who suffer from severe bacterial infection, in China.
Zhong Lun Law Firm acted as the PRC legal counsel of Gosun in this license-in project, advising a number of regulatory, legal and commercial issues in connection with the transaction including clinical trials, supply of raw materials, mechanism for royalty payment, licensing and IP protection, imported drug registration, and domestic drug registration, participating and assisting in the negotiation, and reviewing and revising the license agreement. The legal team from Zhong Lun was led by Helen Cheng, Yue Han and Emily Wang, and included Siqing Wang, Paul Li and Raymond Xu etc.